

Hyeon-Seok Eom

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2626273/publications.pdf>

Version: 2024-02-01

74
papers

854
citations

623734

14
h-index

552781

26
g-index

74
all docs

74
docs citations

74
times ranked

1583
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts. <i>Cancer Research and Treatment</i> , 2023, 55, 325-333.	3.0	2
2	Influence of creatinine levels on survival in patients with veno-occlusive disease treated with defibrotide. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 179-189.	1.7	2
3	Guillain-Barré syndrome after vaccination against COVID-19. <i>Lancet Neurology</i> , The, 2022, 21, 117-119.	10.2	27
4	Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma. <i>Blood Advances</i> , 2022, 6, 3472-3479.	5.2	12
5	Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805). <i>International Journal of Hematology</i> , 2022, , 1.	1.6	0
6	Analysis of laboratory parameters for optimal autologous peripheral blood stem cell collection from lymphoma and myeloma patients. <i>Journal of Clinical Apheresis</i> , 2021, 36, 135-142.	1.3	4
7	Comparison of spectra optia and amicus cell separators for autologous peripheral blood stem cell collection. <i>Journal of Clinical Apheresis</i> , 2021, 36, 28-33.	1.3	4
8	High level of pre-treatment C-reactive protein to albumin ratio predicts inferior prognosis in diffuse large B-cell lymphoma. <i>Scientific Reports</i> , 2021, 11, 2674.	3.3	6
9	Current Use of Total Body Irradiation in Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Korean Medical Science</i> , 2021, 36, e55.	2.5	2
10	Recent Clinical Update of Acute Myeloid Leukemia: Focus on Epigenetic Therapies. <i>Journal of Korean Medical Science</i> , 2021, 36, e85.	2.5	6
11	Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis. <i>Cancer Communications</i> , 2021, 41, 275-278.	9.2	4
12	Limited benefits of thalidomide and dexamethasone maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma patients: a prospective phase II multi-center study in Korea. <i>Current Problems in Cancer</i> , 2021, 46, 100786.	2.0	0
13	Pegfilgrastim Prophylaxis is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study. <i>Cancer Research and Treatment</i> , 2021, , .	3.0	4
14	Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e97-e104.	0.4	2
15	A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2020, 99, 255-264.	1.8	3
16	Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea: the KMM1807 study. <i>International Journal of Hematology</i> , 2020, 112, 84-95.	1.6	5
17	Development of an Automated Image Analyzer for Microvessel Density Measurement in Bone Marrow Biopsies. <i>Annals of Laboratory Medicine</i> , 2020, 40, 312-316.	2.5	0
18	Prognostic Value of Platelet Count in Patients with Peripheral T Cell Lymphoma. <i>Acta Haematologica</i> , 2019, 141, 176-186.	1.4	16

#	ARTICLE	IF	CITATIONS
19	Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 923-929.	2.0	10
20	Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy. <i>Investigational New Drugs</i> , 2018, 36, 877-885.	2.6	5
21	Nationwide Statistical Analysis of Lymphoid Malignancies in Korea. <i>Cancer Research and Treatment</i> , 2018, 50, 222-238.	3.0	47
22	Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2471-2478.	2.0	24
23	Prognostic Implications of Monosomies in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 159-164.e2.	0.4	10
24	Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study. <i>Cancer Medicine</i> , 2017, 6, 100-108.	2.8	5
25	Adverse prognostic impact of vascular endothelial growth factor gene polymorphisms in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2677-2682.	1.3	7
26	Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. <i>American Journal of Hematology</i> , 2017, 92, 1280-1286.	4.1	34
27	Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort. <i>Blood Research</i> , 2017, 52, 207.	1.3	11
28	A Case of Disseminated Infection with Skin Manifestation due to Non- <i>neoformans</i> and Non- <i>gattii</i> <i>Cryptococcus</i> in a Patient with Refractory Acute Myeloid Leukemia. <i>Infection and Chemotherapy</i> , 2017, 49, 142.	2.3	12
29	Prognostic role of the neutrophil-to-lymphocyte ratio in patients with primary central nervous system lymphoma. <i>Oncotarget</i> , 2017, 8, 74975-74986.	1.8	17
30	Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 92171-92182.	1.8	12
31	A Case of Disseminated Infection with Skin Manifestation due to Non- <i>neoformans</i> and Non- <i>gattii</i> <i>Cryptococcus</i> in a Patient with Refractory Acute Myeloid Leukemia. <i>Infection and Chemotherapy</i> , 2017, 49, 142.	2.3	0
32	Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party. <i>Blood Research</i> , 2016, 51, 193.	1.3	6
33	Radiation therapy for gastric mucosa-associated lymphoid tissue lymphoma: dose-volumetric analysis and its clinical implications. <i>Radiation Oncology Journal</i> , 2016, 34, 193-201.	1.5	8
34	Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive Tumors. <i>Journal of Immunotherapy</i> , 2016, 39, 140-148.	2.4	16
35	The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase. <i>Annals of Hematology</i> , 2016, 95, 1491-1501.	1.8	9
36	Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 527-535.e2.	0.4	23

#	ARTICLE	IF	CITATIONS
37	Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF. <i>Leukemia and Lymphoma</i> , 2016, 57, 1389-1397.	1.3	6
38	A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial. <i>Leukemia and Lymphoma</i> , 2016, 57, 1406-1412.	1.3	4
39	Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study. <i>Oncotarget</i> , 2016, 7, 72033-72043.	1.8	14
40	Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. <i>Blood</i> , 2015, 126, 746-756.	1.4	160
41	Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2015, 90, 1013-1020.	4.1	37
42	Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012. <i>Blood Research</i> , 2015, 50, 204.	1.3	44
43	Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea. <i>Blood Research</i> , 2015, 50, 7.	1.3	4
44	Adverse Prognostic Impact of Bone Marrow Microvessel Density in Multiple Myeloma. <i>Annals of Laboratory Medicine</i> , 2015, 35, 563-569.	2.5	15
45	Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation. <i>Blood Research</i> , 2015, 50, 160.	1.3	3
46	Low-dose cisplatin converts the tumor microenvironment into a permissive state for HSVtk-induced antitumor immunity in HPV16-related tonsillar carcinoma. <i>Cancer Letters</i> , 2015, 356, 743-750.	7.2	6
47	The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 675-683.	1.7	2
48	Elevated Red Blood Cell Distribution Width as a Simple Prognostic Factor in Patients with Symptomatic Multiple Myeloma. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	62
49	Rapid Sequential Gain of ABL1 Kinase Domain Mutations with a Complex Karyotype in the Progression of Chronic Myelogenous Leukemia. <i>Annals of Laboratory Medicine</i> , 2014, 34, 399-401.	2.5	0
50	R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma. <i>Blood Research</i> , 2014, 49, 107.	1.3	10
51	Expression of Myeloid Antigen in Neoplastic Plasma Cells Is Related to Adverse Prognosis in Patients with Multiple Myeloma. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	18
52	Impact of Renal Impairment (RI) on Outcomes after Treatment (Tx) with Lenalidomide and Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): First Trial Results. <i>Blood</i> , 2014, 124, 2112-2112.	1.4	1
53	Hematopoietic Progenitor Cell Counts Is a Useful Indicator To Determine Appropriate Time For Peripheral Blood Stem Cell Collection. <i>Blood</i> , 2013, 122, 2037-2037.	1.4	0
54	Nilotinib Combined With Multi-Agent Chemotherapy For Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Final Results Of Prospective Multicenter Phase 2 Study. <i>Blood</i> , 2013, 122, 55-55.	1.4	4

#	ARTICLE	IF	CITATIONS
55	Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL). <i>Annals of Hematology</i> , 2012, 91, 223-233.	1.8	11
56	Adverse Prognostic Impact of Vascular Endothelial Growth Factor Gene Polymorphism in Patients with Non-Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 2674-2674.	1.4	0
57	A Retrospective Study to Evaluate the Survival Rates in R-CHOP Chemotherapy Followed by Autologous Stem Cell Transplantation for the Treatment of Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2012, 120, 4517-4517.	1.4	2
58	Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 632 High-Dose Therapy with ASCT for Newly Diagnosed Multiple Myeloma; Open-Labeled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis. <i>Blood</i> , 2012, 120, 3106-3106.	1.4	7
59	Phase I Study of mTOR Inhibitor Everolimus Plus CHOP in Patients with Advanced, Aggressive T-Cell lymphomas. <i>Blood</i> , 2011, 118, 1642-1642.	1.4	2
60	Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 557 by High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma; Open-Labelled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis. <i>Blood</i> , 2011, 118, 2044-2044.	1.4	19
61	Effects of Prophylactic Defibrotide for Veno-Occlusive Disease in Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 4517-4517.	1.4	0
62	Response Assessment Using Early and End-of-Treatment 18F-FLT PET Can Predict Outcome in Patients with Non-Hodgkin Lymphoma. <i>Blood</i> , 2011, 118, 3679-3679.	1.4	0
63	Matched-Pair Analysis Comparing Outcomes of Second Autologous Stem Cell Transplantation and Chemotherapy As a Salvage Therapy in Patients with Multiple Myeloma Who Relapsed After Front-Line Autologous Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 1990-1990.	1.4	0
64	Bortezomib Induction Followed by ASCT in Patients with Multiple Myeloma: Achievement of Response After Induction and Achieving CR Post-ASCT Are Both Important Prognostic Markers. <i>Blood</i> , 2011, 118, 1866-1866.	1.4	0
65	Early Response to Bortezomib Combined Chemotherapy Can Be Helpful for Prediction of Progression Free Survival in Patients with Multiple Myeloma Who Were Ineligible for Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 5138-5138.	1.4	0
66	Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP). <i>Annals of Hematology</i> , 2010, 89, 489-497.	1.8	12
67	Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party. <i>International Journal of Hematology</i> , 2010, 92, 52-57.	1.6	41
68	The Efficacy of Bortezomib-CHOP In Patients with Advanced Stage T or NK/T Cell Lymphomas: The Results of Multicenter Phase II Study. <i>Blood</i> , 2010, 116, 1791-1791.	1.4	2
69	Concurrent Chemo-Radiotherapy Followed by VIDL (Etoposide, Ifosfamide, Dexamethasone,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 632 <i>Blood</i> , 2010, 116, 1765-1765.	1.4	0
70	Prognostic Significance of Immune Thrombocytopenic Purpura In Patients with Malignancy. <i>Blood</i> , 2010, 116, 1428-1428.	1.4	0
71	A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 27-33.	2.3	9
72	Fluorescent in Situ Hybridization Analysis at Bone Marrow Biopsy Section in Multiple Myeloma. <i>Blood</i> , 2009, 114, 4898-4898.	1.4	0

#	ARTICLE	IF	CITATIONS
	Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (VELCADE [®] , Thalidomide,) Tj ETQq1 1 0.784314 rgBT /Overlock	1.4	4
73	Transplantation and Maintenance Treatment with VELCADE for Newly Diagnosed Multiple Myeloma: Interim Results of Phase II Trial.. Blood, 2007, 110, 952-952.	1.4	4
74	A Multicenter Phase II Trial of Etoposide, Methylprednisolone, High-Dose Cytarabine, and Oxaliplatin (ESHAOx) for Patients with Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma.. Blood, 2007, 110, 3446-3446.	1.4	0